- Home
- CNTA vs LEGN Comparison
CNTA vs LEGN Comparison
Compare CNTA & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTA | LEGN |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.9B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CNTA | LEGN |
|---|---|---|
| Price | $39.68 | $33.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $43.17 | ★ $61.33 |
| AVG Volume (30 Days) | 1.1M | ★ 2.8M |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,000,000.00 | N/A |
| Revenue This Year | N/A | $42.68 |
| Revenue Next Year | N/A | $30.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.55 | $16.24 |
| 52 Week High | $40.26 | $45.30 |
Technical Indicators
Market Signals| Indicator | CNTA | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 62.46 | 60.90 |
| Support Level | $39.36 | $31.84 |
| Resistance Level | $39.86 | $34.54 |
| Average True Range (ATR) | 0.13 | 2.59 |
| MACD | -0.15 | 0.42 |
| Stochastic Oscillator | 25.93 | 63.44 |
Price Performance
Historical ComparisonAbout CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.